Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug;10(Suppl 21):S2492-S2507.
doi: 10.21037/jtd.2018.05.73.

Combining immunotherapy with radiation therapy in thoracic oncology

Shahed N Badiyan  1 , Michael C Roach  2 , Michael D Chuong  3 , Stephanie R Rice  1 , Nasarachi E Onyeuku  1 , Jill Remick  1 , Srinivas Chilukuri  4 , Erica Glass  1 , Pranshu Mohindra  1 , Charles B Simone 2nd  1
Affiliations
Review

Combining immunotherapy with radiation therapy in thoracic oncology

Shahed N Badiyan et al. J Thorac Dis. 2018 Aug.

Abstract

Thoracic malignancies comprise some of the most common and deadly cancers. Immunotherapies have been proven to improve survival outcomes for patients with advanced non-small cell lung cancer (NSCLC) and show great potential for patients with other thoracic malignancies. Radiation therapy (RT), an established and effective treatment for thoracic cancers, has acted synergistically with immunotherapies in preclinical studies. Ongoing clinical trials are exploring the clinical benefits of combining RT with immunotherapies and the optimal manner in which to deliver these complementary treatments.

Keywords: Radiation therapy (RT); esophageal cancer; immune checkpoint inhibitors (ICIs); immunotherapy; lung cancer; mesothelioma; thymoma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Badiyan and Dr. Simone have speaker’s honoraria from Varian Medical Systems.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. 10.3322/caac.21442 - DOI - PubMed
    1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. 10.1200/JCO.2003.11.136 - DOI - PubMed
    1. Suntharalingam M, Winter K, Ilson D, et al. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer. JAMA Oncol 2017;3:1520-8. 10.1001/jamaoncol.2017.1598 - DOI - PMC - PubMed
    1. Jackson MW, Palma DA, Camidge DR, et al. The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma. J Thorac Oncol 2017;12:734-44. 10.1016/j.jtho.2017.01.002 - DOI - PubMed
    1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342:1432-3. 10.1126/science.342.6165.1432 - DOI - PubMed

LinkOut - more resources